» Articles » PMID: 37508486

Epigenetic Modifications of MiRNAs in Osteoarthritis: A Systematic Review on Their Methylation Levels and Effects on Chondrocytes, Extracellular Matrix and Joint Inflammation

Overview
Journal Cells
Publisher MDPI
Date 2023 Jul 29
PMID 37508486
Authors
Affiliations
Soon will be listed here.
Abstract

Osteoarthritis (OA) is a joint disorder characterized by progressive degeneration of cartilage extracellular matrix (ECM), chondrocyte hypertrophy and apoptosis and inflammation. The current treatments mainly concern pain control and reduction of inflammation, but no therapeutic strategy has been identified as a disease-modifying treatment. Therefore, identifying specific biomarkers useful to prevent, treat or distinguish the stages of OA disease has become an immediate need of clinical practice. The role of microRNAs (miRNAs) in OA has been investigated in the last decade, and increasing evidence has emerged that the influence of the environment on gene expression through epigenetic processes contributes to the development, progression and aggressiveness of OA, in particular acting on the microenvironment modulations. The effects of epigenetic regulation, particularly different miRNA methylation during OA disease, were highlighted in the present systematic review. The evidence arising from this study of the literature conducted in three databases (PubMed, Scopus, Web of Science) suggested that miRNA methylation state already strongly impacts OA progression, driving chondrocytes and synoviocyte proliferation, apoptosis, inflammation and ECM deposition. However, the possibility of understanding the mechanism by which different epigenetic modifications of miRNA or pre-miRNA sequences drive the aggressiveness of OA could be the new focus of future investigations.

Citing Articles

MiR203a-3p as a potential biomarker for synovial pathology associated with osteoarthritis: a pilot study.

Costa V, Terrando S, Bellavia D, Salvatore C, Alessandro R, Giavaresi G J Orthop Surg Res. 2024; 19(1):746.

PMID: 39533317 PMC: 11558974. DOI: 10.1186/s13018-024-05237-2.


Efficacy of Anti-Interleukin-1 Therapeutics in the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials from the Years 2000 to 2023.

Knapik M, Zelazo D, Osowiecka K, Krajewska-Wlodarczyk M J Clin Med. 2024; 13(10).

PMID: 38792403 PMC: 11121880. DOI: 10.3390/jcm13102859.

References
1.
Gambari L, Cellamare A, Grassi F, Grigolo B, Panciera A, Ruffilli A . Overview of Anti-Inflammatory and Anti-Nociceptive Effects of Polyphenols to Halt Osteoarthritis: From Preclinical Studies to New Clinical Insights. Int J Mol Sci. 2022; 23(24). PMC: 9779856. DOI: 10.3390/ijms232415861. View

2.
Wang M, Shen J, Jin H, Im H, Sandy J, Chen D . Recent progress in understanding molecular mechanisms of cartilage degeneration during osteoarthritis. Ann N Y Acad Sci. 2011; 1240:61-9. PMC: 3671949. DOI: 10.1111/j.1749-6632.2011.06258.x. View

3.
Diaz-Prado S, Cicione C, Muinos-Lopez E, Hermida-Gomez T, Oreiro N, Fernandez-Lopez C . Characterization of microRNA expression profiles in normal and osteoarthritic human chondrocytes. BMC Musculoskelet Disord. 2012; 13:144. PMC: 3495209. DOI: 10.1186/1471-2474-13-144. View

4.
Yue S, Su X, Teng J, Wang J, Guo M . Cryptotanshinone interferes with chondrocyte apoptosis in osteoarthritis by inhibiting the expression of miR‑574‑5p. Mol Med Rep. 2021; 23(6). PMC: 8047883. DOI: 10.3892/mmr.2021.12063. View

5.
Yang X, Chen L, Xu X, Li C, Huang C, Deng C . TGF-beta/Smad3 signals repress chondrocyte hypertrophic differentiation and are required for maintaining articular cartilage. J Cell Biol. 2001; 153(1):35-46. PMC: 2185521. DOI: 10.1083/jcb.153.1.35. View